Clinical Trial Update: Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase I-II trial to find the maximum tolerated dose of AUY922 in advanced solid malignancies and assess efficacy in HER2+ or ER+ locally advanced or metastatic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AUY922 (luminespib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer, Hematologic Neoplasms | Phase 1, Phase 2 | Status: COMPLETED